InvestorsObserver
×
News Home

AbCellera Biologics Inc (ABCL) Stock: Do Analysts Think You Should Hold?

Thursday, December 02, 2021 01:35 PM | InvestorsObserver Analysts

Mentioned in this article

AbCellera Biologics Inc (ABCL) Stock: Do Analysts Think You Should Hold?

Analysts who follow AbCellera Biologics Inc (ABCL) on average expect it to climb 179.26% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 74, which means it ranks higher than 74 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating ABCL a Strong Buy today. Find out what this means to you and get the rest of the rankings on ABCL!

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With AbCellera Biologics Inc Stock Today?

AbCellera Biologics Inc (ABCL) stock is trading at $14.61 as of 1:20 PM on Thursday, Dec 2, a rise of $0.03, or 0.21% from the previous closing price of $14.58. Volume today is light. So far 562,645 shares have traded compared to average volume of 1,715,809 shares. The stock has traded between $14.09 and $14.79 so far today. Click Here to get the full Stock Report for AbCellera Biologics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App